High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection
Background. Randomized controlled trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9 months of isoniazid, with a greater completion rate (82% vs 69%); however, 3HP has not been asse...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2017-10, Vol.65 (7), p.1085-1093 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1093 |
|---|---|
| container_issue | 7 |
| container_start_page | 1085 |
| container_title | Clinical infectious diseases |
| container_volume | 65 |
| creator | Sandul, Amy L. Nwana, Nwabunie Holcombe, J. Mike Lobato, Mark N. Marks, Suzanne Webb, Risa Wang, Shu-Hua Stewart, Brock Griffin, Phil Hunt, Garrett Shah, Neha Marco, Asween Patil, Naveen Mukasa, Leonard Moro, Ruth N. Jereb, John Mase, Sundari Chorba, Terence Bamrah-Morris, Sapna Ho, Christine S. |
| description | Background. Randomized controlled trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9 months of isoniazid, with a greater completion rate (82% vs 69%); however, 3HP has not been assessed in routine healthcare settings. Methods. Observational cohort of LTBI patients receiving 3HP through 16 US programs was used to assess treatment completion, adverse drug reactions, and factors associated with treatment discontinuation. Results. Of 3288 patients eligible to complete 3HP, 2867 (87.2%) completed treatment. Children aged 2–17 years had the highest completion rate (94.5% [155/164]). Patients reporting homelessness had a completion rate of 81.2% (147/181). In univariable analyses, discontinuation was lowest among children (relative risk [RR], 0.44 [95% confidence interval {CI}, .23–.85]; P = .014), and highest in persons aged ≥65 years (RR, 1.72 [95% CI, 1.25–2.35]; P < .001). In multivariable analyses, discontinuation was lowest among contacts of patients with tuberculosis (TB) disease (adjusted RR [ARR], 0.68 [95% CI, .52–.89]; P = .005) and students (ARR, 0.45 [95% CI, .21–.98]; P = .044), and highest with incarceration (ARR, 1.43 [95% CI, 1.08–1.89]; P = .013) and homelessness (ARR, 1.72 [95% CI, 1.25–2.39]; P = .001). Adverse drug reactions were reported by 1174 (35.7%) patients, of whom 891 (76.0%) completed treatment. Conclusions. Completion of 3HP in routine healthcare settings was greater overall than rates reported from clinical trials, and greater than historically observed using other regimens among reportedly nonadherent populations. Widespread use of 3HP for LTBI treatment could accelerate elimination of TB disease in the United States. |
| doi_str_mv | 10.1093/cid/cix505 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5709238</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>26375709</jstor_id><sourcerecordid>26375709</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-a7f72f576e23a37a52f3c347819b72690893a16fc27ec421b464585796ab258c3</originalsourceid><addsrcrecordid>eNpdkV1rFDEYhQdRbK3eeK8EvJHC1HxOMjeCrB9d2KLUSi-HTPbNbtaZZE0y4vo3-ofNsrV-XIQE3ifnPYdTVU8JPiO4Za-MW5bzQ2Bxrzomgsm6ES25X95YqJorpo6qRyltMCZEYfGwOqJKSEGxOq5uzt1qjS51BhQsuoqg8wg-o1kYtwNkFzxyHn2KYRX1iD5Dzs6vErp2eY0Ird-GBOga4OuwQ_MUvNM_3RJpv0SXzuptUXIekA0RLcqKonuxM6HXJkN004jy1EM00xCSS2juLZj9xsfVA6uHBE9u75Pqy_t3V7PzevHxw3z2ZlEbTlWutbSSWiEboEwzqQW1zDAuFWl7SZsWq5Zp0lhDJZQfpOcNFyV42-ieCmXYSfX6oLud-hGWpviLeui20Y067rqgXffvxLt1twrfOyFxS5kqAi9vBWL4NkHK3eiSgWHQHsKUOtJiIRnnzR598R-6CVP0JV6hBOeUK9wU6vRAmRhSimDvzBDc7bvuStfdoesCP__b_h36u9wCPDsAm5RD_DNvmNwnYL8Anp6xKw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1954424806</pqid></control><display><type>article</type><title>High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection</title><source>Jstor Complete Legacy</source><source>MEDLINE</source><source>Oxford University Press Journals Current</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Sandul, Amy L. ; Nwana, Nwabunie ; Holcombe, J. Mike ; Lobato, Mark N. ; Marks, Suzanne ; Webb, Risa ; Wang, Shu-Hua ; Stewart, Brock ; Griffin, Phil ; Hunt, Garrett ; Shah, Neha ; Marco, Asween ; Patil, Naveen ; Mukasa, Leonard ; Moro, Ruth N. ; Jereb, John ; Mase, Sundari ; Chorba, Terence ; Bamrah-Morris, Sapna ; Ho, Christine S.</creator><creatorcontrib>Sandul, Amy L. ; Nwana, Nwabunie ; Holcombe, J. Mike ; Lobato, Mark N. ; Marks, Suzanne ; Webb, Risa ; Wang, Shu-Hua ; Stewart, Brock ; Griffin, Phil ; Hunt, Garrett ; Shah, Neha ; Marco, Asween ; Patil, Naveen ; Mukasa, Leonard ; Moro, Ruth N. ; Jereb, John ; Mase, Sundari ; Chorba, Terence ; Bamrah-Morris, Sapna ; Ho, Christine S.</creatorcontrib><description>Background. Randomized controlled trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9 months of isoniazid, with a greater completion rate (82% vs 69%); however, 3HP has not been assessed in routine healthcare settings. Methods. Observational cohort of LTBI patients receiving 3HP through 16 US programs was used to assess treatment completion, adverse drug reactions, and factors associated with treatment discontinuation. Results. Of 3288 patients eligible to complete 3HP, 2867 (87.2%) completed treatment. Children aged 2–17 years had the highest completion rate (94.5% [155/164]). Patients reporting homelessness had a completion rate of 81.2% (147/181). In univariable analyses, discontinuation was lowest among children (relative risk [RR], 0.44 [95% confidence interval {CI}, .23–.85]; P = .014), and highest in persons aged ≥65 years (RR, 1.72 [95% CI, 1.25–2.35]; P < .001). In multivariable analyses, discontinuation was lowest among contacts of patients with tuberculosis (TB) disease (adjusted RR [ARR], 0.68 [95% CI, .52–.89]; P = .005) and students (ARR, 0.45 [95% CI, .21–.98]; P = .044), and highest with incarceration (ARR, 1.43 [95% CI, 1.08–1.89]; P = .013) and homelessness (ARR, 1.72 [95% CI, 1.25–2.39]; P = .001). Adverse drug reactions were reported by 1174 (35.7%) patients, of whom 891 (76.0%) completed treatment. Conclusions. Completion of 3HP in routine healthcare settings was greater overall than rates reported from clinical trials, and greater than historically observed using other regimens among reportedly nonadherent populations. Widespread use of 3HP for LTBI treatment could accelerate elimination of TB disease in the United States.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/cix505</identifier><identifier>PMID: 28575208</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Adolescent ; Adult ; Aged ; Antibiotics ; Antibiotics, Antitubercular - adverse effects ; Antibiotics, Antitubercular - therapeutic use ; Antitubercular Agents - adverse effects ; Antitubercular Agents - therapeutic use ; ARTICLES AND COMMENTARIES ; Child ; Child, Preschool ; Children ; Clinical trials ; Confidence intervals ; Dosage ; Drug Administration Schedule ; Drug dosages ; Drug Therapy, Combination - adverse effects ; Drug Therapy, Combination - methods ; Drug-Related Side Effects and Adverse Reactions - etiology ; Female ; Health care ; Historical account ; Homeless people ; Homeless Persons ; Homelessness ; Humans ; Isoniazid ; Isoniazid - adverse effects ; Isoniazid - therapeutic use ; Latent Tuberculosis - drug therapy ; Male ; Medical research ; Medical treatment ; Middle Aged ; Mycobacterium tuberculosis - drug effects ; Patients ; Rifampin - adverse effects ; Rifampin - analogs & derivatives ; Rifampin - therapeutic use ; Side effects ; Students ; Tuberculosis ; United States ; Young Adult</subject><ispartof>Clinical infectious diseases, 2017-10, Vol.65 (7), p.1085-1093</ispartof><rights>Copyright © 2017 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>Copyright Oxford University Press, UK Oct 1, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-a7f72f576e23a37a52f3c347819b72690893a16fc27ec421b464585796ab258c3</citedby><cites>FETCH-LOGICAL-c428t-a7f72f576e23a37a52f3c347819b72690893a16fc27ec421b464585796ab258c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/26375709$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/26375709$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,776,780,799,881,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28575208$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sandul, Amy L.</creatorcontrib><creatorcontrib>Nwana, Nwabunie</creatorcontrib><creatorcontrib>Holcombe, J. Mike</creatorcontrib><creatorcontrib>Lobato, Mark N.</creatorcontrib><creatorcontrib>Marks, Suzanne</creatorcontrib><creatorcontrib>Webb, Risa</creatorcontrib><creatorcontrib>Wang, Shu-Hua</creatorcontrib><creatorcontrib>Stewart, Brock</creatorcontrib><creatorcontrib>Griffin, Phil</creatorcontrib><creatorcontrib>Hunt, Garrett</creatorcontrib><creatorcontrib>Shah, Neha</creatorcontrib><creatorcontrib>Marco, Asween</creatorcontrib><creatorcontrib>Patil, Naveen</creatorcontrib><creatorcontrib>Mukasa, Leonard</creatorcontrib><creatorcontrib>Moro, Ruth N.</creatorcontrib><creatorcontrib>Jereb, John</creatorcontrib><creatorcontrib>Mase, Sundari</creatorcontrib><creatorcontrib>Chorba, Terence</creatorcontrib><creatorcontrib>Bamrah-Morris, Sapna</creatorcontrib><creatorcontrib>Ho, Christine S.</creatorcontrib><title>High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Background. Randomized controlled trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9 months of isoniazid, with a greater completion rate (82% vs 69%); however, 3HP has not been assessed in routine healthcare settings. Methods. Observational cohort of LTBI patients receiving 3HP through 16 US programs was used to assess treatment completion, adverse drug reactions, and factors associated with treatment discontinuation. Results. Of 3288 patients eligible to complete 3HP, 2867 (87.2%) completed treatment. Children aged 2–17 years had the highest completion rate (94.5% [155/164]). Patients reporting homelessness had a completion rate of 81.2% (147/181). In univariable analyses, discontinuation was lowest among children (relative risk [RR], 0.44 [95% confidence interval {CI}, .23–.85]; P = .014), and highest in persons aged ≥65 years (RR, 1.72 [95% CI, 1.25–2.35]; P < .001). In multivariable analyses, discontinuation was lowest among contacts of patients with tuberculosis (TB) disease (adjusted RR [ARR], 0.68 [95% CI, .52–.89]; P = .005) and students (ARR, 0.45 [95% CI, .21–.98]; P = .044), and highest with incarceration (ARR, 1.43 [95% CI, 1.08–1.89]; P = .013) and homelessness (ARR, 1.72 [95% CI, 1.25–2.39]; P = .001). Adverse drug reactions were reported by 1174 (35.7%) patients, of whom 891 (76.0%) completed treatment. Conclusions. Completion of 3HP in routine healthcare settings was greater overall than rates reported from clinical trials, and greater than historically observed using other regimens among reportedly nonadherent populations. Widespread use of 3HP for LTBI treatment could accelerate elimination of TB disease in the United States.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibiotics</subject><subject>Antibiotics, Antitubercular - adverse effects</subject><subject>Antibiotics, Antitubercular - therapeutic use</subject><subject>Antitubercular Agents - adverse effects</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>ARTICLES AND COMMENTARIES</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Clinical trials</subject><subject>Confidence intervals</subject><subject>Dosage</subject><subject>Drug Administration Schedule</subject><subject>Drug dosages</subject><subject>Drug Therapy, Combination - adverse effects</subject><subject>Drug Therapy, Combination - methods</subject><subject>Drug-Related Side Effects and Adverse Reactions - etiology</subject><subject>Female</subject><subject>Health care</subject><subject>Historical account</subject><subject>Homeless people</subject><subject>Homeless Persons</subject><subject>Homelessness</subject><subject>Humans</subject><subject>Isoniazid</subject><subject>Isoniazid - adverse effects</subject><subject>Isoniazid - therapeutic use</subject><subject>Latent Tuberculosis - drug therapy</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Patients</subject><subject>Rifampin - adverse effects</subject><subject>Rifampin - analogs & derivatives</subject><subject>Rifampin - therapeutic use</subject><subject>Side effects</subject><subject>Students</subject><subject>Tuberculosis</subject><subject>United States</subject><subject>Young Adult</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkV1rFDEYhQdRbK3eeK8EvJHC1HxOMjeCrB9d2KLUSi-HTPbNbtaZZE0y4vo3-ofNsrV-XIQE3ifnPYdTVU8JPiO4Za-MW5bzQ2Bxrzomgsm6ES25X95YqJorpo6qRyltMCZEYfGwOqJKSEGxOq5uzt1qjS51BhQsuoqg8wg-o1kYtwNkFzxyHn2KYRX1iD5Dzs6vErp2eY0Ird-GBOga4OuwQ_MUvNM_3RJpv0SXzuptUXIekA0RLcqKonuxM6HXJkN004jy1EM00xCSS2juLZj9xsfVA6uHBE9u75Pqy_t3V7PzevHxw3z2ZlEbTlWutbSSWiEboEwzqQW1zDAuFWl7SZsWq5Zp0lhDJZQfpOcNFyV42-ieCmXYSfX6oLud-hGWpviLeui20Y067rqgXffvxLt1twrfOyFxS5kqAi9vBWL4NkHK3eiSgWHQHsKUOtJiIRnnzR598R-6CVP0JV6hBOeUK9wU6vRAmRhSimDvzBDc7bvuStfdoesCP__b_h36u9wCPDsAm5RD_DNvmNwnYL8Anp6xKw</recordid><startdate>20171001</startdate><enddate>20171001</enddate><creator>Sandul, Amy L.</creator><creator>Nwana, Nwabunie</creator><creator>Holcombe, J. Mike</creator><creator>Lobato, Mark N.</creator><creator>Marks, Suzanne</creator><creator>Webb, Risa</creator><creator>Wang, Shu-Hua</creator><creator>Stewart, Brock</creator><creator>Griffin, Phil</creator><creator>Hunt, Garrett</creator><creator>Shah, Neha</creator><creator>Marco, Asween</creator><creator>Patil, Naveen</creator><creator>Mukasa, Leonard</creator><creator>Moro, Ruth N.</creator><creator>Jereb, John</creator><creator>Mase, Sundari</creator><creator>Chorba, Terence</creator><creator>Bamrah-Morris, Sapna</creator><creator>Ho, Christine S.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20171001</creationdate><title>High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection</title><author>Sandul, Amy L. ; Nwana, Nwabunie ; Holcombe, J. Mike ; Lobato, Mark N. ; Marks, Suzanne ; Webb, Risa ; Wang, Shu-Hua ; Stewart, Brock ; Griffin, Phil ; Hunt, Garrett ; Shah, Neha ; Marco, Asween ; Patil, Naveen ; Mukasa, Leonard ; Moro, Ruth N. ; Jereb, John ; Mase, Sundari ; Chorba, Terence ; Bamrah-Morris, Sapna ; Ho, Christine S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-a7f72f576e23a37a52f3c347819b72690893a16fc27ec421b464585796ab258c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibiotics</topic><topic>Antibiotics, Antitubercular - adverse effects</topic><topic>Antibiotics, Antitubercular - therapeutic use</topic><topic>Antitubercular Agents - adverse effects</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>ARTICLES AND COMMENTARIES</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Clinical trials</topic><topic>Confidence intervals</topic><topic>Dosage</topic><topic>Drug Administration Schedule</topic><topic>Drug dosages</topic><topic>Drug Therapy, Combination - adverse effects</topic><topic>Drug Therapy, Combination - methods</topic><topic>Drug-Related Side Effects and Adverse Reactions - etiology</topic><topic>Female</topic><topic>Health care</topic><topic>Historical account</topic><topic>Homeless people</topic><topic>Homeless Persons</topic><topic>Homelessness</topic><topic>Humans</topic><topic>Isoniazid</topic><topic>Isoniazid - adverse effects</topic><topic>Isoniazid - therapeutic use</topic><topic>Latent Tuberculosis - drug therapy</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Patients</topic><topic>Rifampin - adverse effects</topic><topic>Rifampin - analogs & derivatives</topic><topic>Rifampin - therapeutic use</topic><topic>Side effects</topic><topic>Students</topic><topic>Tuberculosis</topic><topic>United States</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sandul, Amy L.</creatorcontrib><creatorcontrib>Nwana, Nwabunie</creatorcontrib><creatorcontrib>Holcombe, J. Mike</creatorcontrib><creatorcontrib>Lobato, Mark N.</creatorcontrib><creatorcontrib>Marks, Suzanne</creatorcontrib><creatorcontrib>Webb, Risa</creatorcontrib><creatorcontrib>Wang, Shu-Hua</creatorcontrib><creatorcontrib>Stewart, Brock</creatorcontrib><creatorcontrib>Griffin, Phil</creatorcontrib><creatorcontrib>Hunt, Garrett</creatorcontrib><creatorcontrib>Shah, Neha</creatorcontrib><creatorcontrib>Marco, Asween</creatorcontrib><creatorcontrib>Patil, Naveen</creatorcontrib><creatorcontrib>Mukasa, Leonard</creatorcontrib><creatorcontrib>Moro, Ruth N.</creatorcontrib><creatorcontrib>Jereb, John</creatorcontrib><creatorcontrib>Mase, Sundari</creatorcontrib><creatorcontrib>Chorba, Terence</creatorcontrib><creatorcontrib>Bamrah-Morris, Sapna</creatorcontrib><creatorcontrib>Ho, Christine S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sandul, Amy L.</au><au>Nwana, Nwabunie</au><au>Holcombe, J. Mike</au><au>Lobato, Mark N.</au><au>Marks, Suzanne</au><au>Webb, Risa</au><au>Wang, Shu-Hua</au><au>Stewart, Brock</au><au>Griffin, Phil</au><au>Hunt, Garrett</au><au>Shah, Neha</au><au>Marco, Asween</au><au>Patil, Naveen</au><au>Mukasa, Leonard</au><au>Moro, Ruth N.</au><au>Jereb, John</au><au>Mase, Sundari</au><au>Chorba, Terence</au><au>Bamrah-Morris, Sapna</au><au>Ho, Christine S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2017-10-01</date><risdate>2017</risdate><volume>65</volume><issue>7</issue><spage>1085</spage><epage>1093</epage><pages>1085-1093</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Background. Randomized controlled trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9 months of isoniazid, with a greater completion rate (82% vs 69%); however, 3HP has not been assessed in routine healthcare settings. Methods. Observational cohort of LTBI patients receiving 3HP through 16 US programs was used to assess treatment completion, adverse drug reactions, and factors associated with treatment discontinuation. Results. Of 3288 patients eligible to complete 3HP, 2867 (87.2%) completed treatment. Children aged 2–17 years had the highest completion rate (94.5% [155/164]). Patients reporting homelessness had a completion rate of 81.2% (147/181). In univariable analyses, discontinuation was lowest among children (relative risk [RR], 0.44 [95% confidence interval {CI}, .23–.85]; P = .014), and highest in persons aged ≥65 years (RR, 1.72 [95% CI, 1.25–2.35]; P < .001). In multivariable analyses, discontinuation was lowest among contacts of patients with tuberculosis (TB) disease (adjusted RR [ARR], 0.68 [95% CI, .52–.89]; P = .005) and students (ARR, 0.45 [95% CI, .21–.98]; P = .044), and highest with incarceration (ARR, 1.43 [95% CI, 1.08–1.89]; P = .013) and homelessness (ARR, 1.72 [95% CI, 1.25–2.39]; P = .001). Adverse drug reactions were reported by 1174 (35.7%) patients, of whom 891 (76.0%) completed treatment. Conclusions. Completion of 3HP in routine healthcare settings was greater overall than rates reported from clinical trials, and greater than historically observed using other regimens among reportedly nonadherent populations. Widespread use of 3HP for LTBI treatment could accelerate elimination of TB disease in the United States.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>28575208</pmid><doi>10.1093/cid/cix505</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2017-10, Vol.65 (7), p.1085-1093 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5709238 |
| source | Jstor Complete Legacy; MEDLINE; Oxford University Press Journals Current; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Antibiotics Antibiotics, Antitubercular - adverse effects Antibiotics, Antitubercular - therapeutic use Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use ARTICLES AND COMMENTARIES Child Child, Preschool Children Clinical trials Confidence intervals Dosage Drug Administration Schedule Drug dosages Drug Therapy, Combination - adverse effects Drug Therapy, Combination - methods Drug-Related Side Effects and Adverse Reactions - etiology Female Health care Historical account Homeless people Homeless Persons Homelessness Humans Isoniazid Isoniazid - adverse effects Isoniazid - therapeutic use Latent Tuberculosis - drug therapy Male Medical research Medical treatment Middle Aged Mycobacterium tuberculosis - drug effects Patients Rifampin - adverse effects Rifampin - analogs & derivatives Rifampin - therapeutic use Side effects Students Tuberculosis United States Young Adult |
| title | High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A03%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20Rate%20of%20Treatment%20Completion%20in%20Program%20Settings%20With%2012-Dose%20Weekly%20Isoniazid%20and%20Rifapentine%20for%20Latent%20Mycobacterium%20tuberculosis%20Infection&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Sandul,%20Amy%20L.&rft.date=2017-10-01&rft.volume=65&rft.issue=7&rft.spage=1085&rft.epage=1093&rft.pages=1085-1093&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/cix505&rft_dat=%3Cjstor_pubme%3E26375709%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1954424806&rft_id=info:pmid/28575208&rft_jstor_id=26375709&rfr_iscdi=true |